Recommendations for the detection and treatment of peripheral arterial disease

  • Aleš Blinc Klinični oddelek za žilne bolezni Univerzitetni klinični center Ljubljana Zaloška 7 1000 Ljubljana
  • Matija Kozak Klinični oddelek za žilne bolezniUniverzitetni klinični center LjubljanaZaloška 71000 Ljubljana
  • Mišo Šabovič Klinični oddelek za žilne bolezni Univerzitetni klinični center Ljubljana Zaloška 7 1000 Ljubljana
  • Vinko Boc Klinični oddelek za žilne bolezni Univerzitetni klinični center Ljubljana Zaloška 7 1000 Ljubljana
  • Pavel Poredoš Klinični oddelek za žilne bolezni Univerzitetni klinični center Ljubljana Zaloška 7 1000 Ljubljana
  • Vojko Flis Oddelek za žilno kirurgijo Klinika za kirurgijo Univerzitetni klinični center Maribor
  • Silva Breznik Radiološki oddelek Univerzitetni klinični center Maribor
  • Tomaž Ključevšek Klinični inštitut za radiologijo Univerzitetni klinični center Ljubljana
  • Dimitrij Kuhelj Klinični inštitut za radiologijo Univerzitetni klinični center Ljubljana
  • Mladen Gasparini Odsek za vaskularno kirurgijo Oddelek za kirurgijo Splošna bolnišnica Izola
  • Klemen Kerin Žilni odsek Kirurški oddelek Splošna bolnišnica Novo mesto
  • Ivan Žuran Oddelek za angiologijo, endokrinologijo in revmatologijo Splošna bolnišnica Celje
  • Janez Poklukar Oddelek za interno medicino Splošna bolnišnica Jesenice
  • Vladimir Valentinuzzi Oddelek za žilno kirurgijo Kirurška služba Splošna bolnišnica »Dr. Franca Derganca« Nova Gorica
  • Tomislav Klokočovnik Klinični oddelek za kirurgijo srca in ožilja Kirurška klinika Univerzitetni klinični center Ljubljana
DOI: https://doi.org/10.6016/ZdravVestn.2509
Keywords: peripheral arterial disease, risk factors, percutaneous procedures, surgery

Abstract

In the article, recommendations for the diagnostics in suspected peripheral arterial disease are presented together with therapeutic procedures and long-term follow-up of the affected patients.

Downloads

Download data is not yet available.

References

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes GR, et al. on behalf of the TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26(2):81–157.

The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–906.

Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment of acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) investigators. N Engl J Med. 1998;338(16):1105–11.

Davies B, Braithwaite BD, Birch PA, Porskitt KR, Heather BP, Earnshaw JJ. Acute leg ischemia in Gloucestershire. Br J Surg. 1997;84(4):504–8.

Costantini V, Lenti M. Treatment of acute occlusion of peripheral arteries. Thromb Res. 2002;106(6):V285–94.

Pentti J, Salenius JP, Kuukasjarvi P, Tarkka M. Outcome of surgical treatment in accute upper limb ischaemia. Ann Chir Gynaecol. 1995;84(1):25–8.

Pemberton M, Varty K, Nydahl S, Bell PR. The surgical management of acute limb ischaemia due to native vessel occlusion. Eur J Vasc Endovasc Surg. 1999;17(1):72–6.

Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion – a consensus document. J Vasc Interv Radiol. 2003;14(9 Pt 2):S337–49.

Morrison HL. Catheter-directed thrombolysis for acute limb ischemia. Semin Intervent Radiol. 2006;23(3):258–69.

Fontaine R, Kim M, Kieny R. Die chirurgische behandlung der peripheren Durchblutungsstörungen. Helv Chir Acta. 1954;21(5–6):499–533.

Rutheford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517–38.

Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–24.

Fowkes GF, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40.

Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 Suppl 1):S117–31.

O’Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12(12):2838–47.

Sinski M, Styczynski G, Szmigelski C. Automated oscillometric measurement of the ankle–brachial index in patients with coronary artery disease. Hypertens Res. 2013;36(1):25–8.

Fleischmann D, Hallett RL, Rubin GD. CT angiography of peripheral arterial diseaseJ Vasc Interv Radiol. 2006;17(1):3–26.

Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer Arch Intern Med. 2009;169(22):2078–86.

Kuhelj D, Zdešar U, Šurlan M, Ključevšek T, Popovič P, Stankovič M, et al. Je izpostavljenost sevanju višja pri CTA kot pri DSA medeničnih in perfernih arterij. In: Blinc A, Kozak M, Šabovič M, eds. Slikovne metode v odkrivanju in zdravljenju žilnih bolezni. Ljubljana: Združenje za žilne bolezni Slovenskega zdravniškega društva; 2005. p. 328–33.

Josephs SC, Rowley HA, Rubin GD, and for Writing Group 3. Atherosclerotic peripheral vascular disease symposium II: vascular magnetic resonance and computed tomographic imaging. Circulation. 2008;118(25):2837–44.

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701.

The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32(14):1769–818

Antithrombotic Trialists’ Collaboration. Collaborative meta-anaysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329–39.

Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study. Lancet. 1992;340(8812):143–5.

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–53.

Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high riskfor vascular events. N Engl J Med. 2008;358(15):1547–59.

Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008;(4):CD000990.

Published
2017-04-15
How to Cite
1.
Blinc A, Kozak M, Šabovič M, Boc V, Poredoš P, Flis V, Breznik S, Ključevšek T, Kuhelj D, Gasparini M, Kerin K, Žuran I, Poklukar J, Valentinuzzi V, Klokočovnik T. Recommendations for the detection and treatment of peripheral arterial disease. TEST ZdravVestn [Internet]. 15Apr.2017 [cited 20Apr.2024];86(3-4):158-76. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2509
Issue
Vol 86 No 3-4 (2017): March-April
Section
Professional Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.